Cited by 311Genomics and Chromatin DynamicsCancer-related Molecular PathwaysChromatin Remodeling and Cancer

The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.

Target gene-independent functions of MYC oncoproteins

Open access

Baluapuri, Apoorva, Wolf, Elmar, Eilers, Martin·2020·Nature Reviews Molecular Cell Biology

DOI 10.1038/s41580-020-0215-2PMC PMC7611238

Open this paper in CoChat — free account

Abstract

Oncoproteins of the MYC family are major drivers of human tumorigenesis. Since a large body of evidence indicates that MYC proteins are transcription factors, studying their function has focused on the biology of their target genes. Detailed studies of MYC-dependent changes in RNA levels have provided contrasting models of the oncogenic activity of MYC proteins through either enhancing or repressing the expression of specific target genes, or as global amplifiers of transcription. In this Review, we first summarize the biochemistry of MYC proteins and what is known (or is unclear) about the MYC target genes. We then discuss recent progress in defining the interactomes of MYC and MYCN and how this information affects central concepts of MYC biology, focusing on mechanisms by which MYC proteins modulate transcription. MYC proteins promote transcription termination upon stalling of RNA polymerase II, and we propose that this mechanism enhances the stress resilience of basal transcription. Furthermore, MYC proteins coordinate transcription elongation with DNA replication and cell cycle progression. Finally, we argue that the mechanism by which MYC proteins regulate the transcription machinery is likely to promote tumorigenesis independently of global or relative changes in the expression of their target genes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41580-020-0215-2

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

MYC on the Path to Cancer
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
A Phase Separation Model for Transcriptional Control
Hnisz, D., Shrinivas, K., Young, R. A., Chakraborty, A. K., & Sharp, P. A. (2017) · Cell · doi:10.1016/j.cell.2017.02.007 · Cited by 1,753
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,543
MYC, Metabolism, and Cancer
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,435
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Self-citation
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells
Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D. R., Tessarollo, L., Casellas, R. C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.033 · Cited by 1,106
Genomic targets of the human c-Myc proteinPreprint
Fernandez, P. C., Frank, S. R., Wang, L., Schroeder, M., Liu, S., Greene, J. R., Cocito, A., & Amati, B. B. (2003) · Genes & Development · doi:10.1101/gad.1067003 · Cited by 963
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation
Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 942

Show all 130 references

Sorted by citations

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 1,044
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 404
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 410
MYC protein interactors in gene transcription and cancer
Lourenco, C., Resetca, D., Redel, C., Lin, P., MacDonald, A. S., Ciaccio, R., Kenney, T. M. G., Wei, Y., Andrews, D. W., Sunnerhagen, M., et al. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00367-9 · Cited by 351
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Wang, J., Yu, X., Gong, W., Liu, X., Park, K., Ma, A., Tsai, Y., Shen, Y., Onikubo, T., Pi, W., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00850-x · Cited by 191
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 193
MYCN Function in Neuroblastoma Development
Otte, J., Dyberg, C. H., Pepich, A., & Johnsen, J. I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624079 · Cited by 191
MYC: a complex problem
Das, S., Lewis, B. A., & Levens, D. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.07.006 · Cited by 166
Targeting transcription cycles in cancer
Vervoort, S. J., Devlin, J. R., Kwiatkowski, N. P., Teng, M., Gray, N. S., & Johnstone, R. W. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 170
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines
Liu, M., Wang, Y., Zhang, Y.-B., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02112-8 · Cited by 189
EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation
Wang, L., Chen, C., Song, Z., Wang, H., Ye, M., Wang, D., Kang, W., Liu, H., & Qing, G. (2022) · Nature Communications · doi:10.1038/s41467-021-27609-6 · Cited by 151
Human embryonic genome activation initiates at the one-cell stage
Asami, M., Lam, B., Ma, M. K. L., Rainbow, K., Braun, S., VerMilyea, M. D., Yeo, G. S. H., & Perry, A. C. F. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.11.012 · Cited by 146
Extrachromosomal circular DNA: biogenesis, structure, functions and diseases
Yang, L., Jia, R., Ge, T., Ge, S., Zhuang, A., Chai, P., & Fan, X. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01176-8 · Cited by 136
Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein
Beaulieu, M.-È., Castillo, F., & Soucek, L. (2020) · Cells · doi:10.3390/cells9041038 · Cited by 110
MYC assembles and stimulates topoisomerases 1 and 2 in a “topoisome”
Das, S., Kuzin, V., Cameron, D. P., Sanford, S., Jha, R. K., Nie, Z., Rosello, M. T., Holewinski, R. J., Andrésson, Þ., Wiśniewski, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.016 · Cited by 112
Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer
Xu, H., Luo, H., Zhang, J., Li, K., & Lee, M. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2186114 · Cited by 110
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 101
Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis
Han, X., Ren, C., Lü, C., Qiao, P., Yang, T., & Yu, Z. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00971-8 · Cited by 103
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma
Röschert, I., Poon, E., Henssen, A. G., García, H. D., Gatti, M., Giansanti, C., Jamin, Y., Ade, C. P., Gallant, P., Schülein‐Völk, C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00171-8 · Cited by 103
Self-citation
Targeting MYCN in Pediatric and Adult Cancers
Liu, Z., Chen, S. S., Clarke, S., Veschi, V., & Thiele, C. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.623679 · Cited by 95
MYC multimers shield stalled replication forks from RNA polymerase
Solvie, D., Baluapuri, A., Uhl, L., Fleischhauer, D., Endres, T., Papadopoulos, D., Aziba, A., Gaballa, A., Mikičić, I., Isaakova, E. A., et al. (2022) · Nature · doi:10.1038/s41586-022-05469-4 · Cited by 95
Self-citation
A review of healthy role of dietary fiber in modulating chronic diseases
Li, M., & Ma, S. (2024) · Food Research International · doi:10.1016/j.foodres.2024.114682 · Cited by 105
MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1
Popay, T. M., Wang, J., Adams, C. M., Howard, G. C., Codreanu, S. G., Sherrod, S. D., MCLEAN, J. A. J., Thomas, L. R., Lorey, S. L., Machida, Y., et al. (2021) · eLife · doi:10.7554/elife.60191 · Cited by 93
Interaction modules that impart specificity to disordered protein
Čermáková, K., & Hodges, H. C. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.01.004 · Cited by 96
GEPIA3: Enhanced drug sensitivity and interaction network analysis for cancer research
Kang, Y.-J., Pan, L., Liu, Y., Rong, Z., Liu, J., & Liu, F. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf423 · Cited by 112
Molecular Crosstalk Between MYC and HIF in Cancer
Li, Y., Sun, X., Qian, D. Z., & Dai, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590576 · Cited by 96
LncRNA SNHG17 interacts with LRPPRC to stabilize c-Myc protein and promote G1/S transition and cell proliferation
Liu, J.-Y., Chen, Y., Feng, H.-H., Chen, Z., Wang, Y., Yang, J., & Zhuang, S. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04238-x · Cited by 75
Current Status and Prospects of Targeted Therapy for Osteosarcoma
Hu, Z., Wen, S., Huo, Z., Wang, Q., Zhao, J., Wang, Z., Chen, Y., Zhang, L., Zhou, F., Guo, Z., et al. (2022) · Cells · doi:10.3390/cells11213507 · Cited by 78
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
Smith, B. A. H., Deutzmann, A., Correa, K. M., Delaveris, C. S., Dhanasekaran, R., Dove, C. G., Sullivan, D. K., Wisnovsky, S., Stark, J. C., Pluvinage, J. V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215376120 · Cited by 74
Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer
Yang, K., Zhang, W., Zhong, L., Xiao, Y., Sahoo, S., Fassan, M., Zeng, K., Magee, P., Garofalo, M., & Shi, L. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01160-x · Cited by 72
High-throughput PRIME-editing screens identify functional DNA variants in the human genome
Ren, X., Yang, H., Nierenberg, J. L., Sun, Y., Chen, J., Beaman, C., Pham, T., Nobuhara, M., Takagi, M. A., Narayan, V., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.021 · Cited by 70
MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts
Papadopoulos, D., Solvie, D., Baluapuri, A., Endres, T., Ha, S. A., Herold, S., Kalb, J., Giansanti, C., Schülein‐Völk, C., Ade, C. P., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.002 · Cited by 58
Self-citation
Molecular Mechanisms of MYCN Dysregulation in Cancers
Liu, R., Shi, P., Wang, Z., Yuan, C., & Cui, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.625332 · Cited by 67
Role of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor Microenvironment
Liu, T., Han, S., Yao, Y., & Zhang, G. (2023) · Cancer Management and Research · doi:10.2147/cmar.s421771 · Cited by 65
Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective
Chen, X., Xu, J., Wang, X., Long, G., You, Q., & Guo, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00037 · Cited by 63
In vivo interactome profiling by enzyme‐catalyzed proximity labeling
Xu, Y., Fan, X., & Hu, Y. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00542-3 · Cited by 64
Two diphosphorylated degrons control c-Myc degradation by the Fbw7 tumor suppressor
Welcker, M., Wang, B., Rusnac, D.-V., Hussaini, Y., Swanger, J., Zheng, N., & Clurman, B. E. (2022) · Science Advances · doi:10.1126/sciadv.abl7872 · Cited by 57
Orphan quality control shapes network dynamics and gene expression
Mark, K. G., Kolla, S., Aguirre, J. D., Garshott, D. M., Schmitt, S., Haakonsen, D. L., Xu, C., Kater, L., Kempf, G., Martínez-González, B., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.015 · Cited by 61
MYC phase separation selectively modulates the transcriptome
Yang, J., Chung, C.-I., Koach, J., Liu, H., Navalkar, A., He, H., Ma, Z., Zhao, Q. C., Yang, X., He, L., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01322-6 · Cited by 67
Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters
Endres, T., Solvie, D., Heidelberger, J. B., Andrioletti, V., Baluapuri, A., Ade, C. P., Muhar, M., Eilers, U., Vos, S. M., Cramer, P., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.035 · Cited by 57
Self-citation
Targeting Myc-driven stress addiction in colorectal cancer
Saeed, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100963 · Cited by 56
Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy
Sun, X., Li, Y., Sears, R. C., & Dai, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679445 · Cited by 55
Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer
Shi, W., Wang, Y., Xu, C., Li, Y., Ge, S., Bai, B., Zhang, K., Wang, Y., Zheng, N., Wang, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35797-6 · Cited by 50
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma
Nakauma‐González, J. A., Rijnders, M., van Riet, J., van der Heijden, M. S., Voortman, J., Cuppen, E. P. J. G., Mehra, N., van Wilpe, S., Oosting, S. F., Rijstenberg, L. L., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.01.026 · Cited by 50
Tilting MYC toward cancer cell death
Harrington, C. T., Sotillo, E., Dang, C. V., & Thomas‐Tikhonenko, A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.08.002 · Cited by 48
Dual-role transcription factors stabilize intermediate expression levels
He, J., Huo, X., Pei, G., Jia, Z., Yan, Y., Yu, J., Qu, H., Xie, Y., Yuan, J., Zheng, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.023 · Cited by 46
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
Ma, J., Li, L., Ma, B., Liu, T., Wang, Z., Ye, Q., Peng, Y., Wang, B., Chen, Y., Xu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45796-w · Cited by 48
MYC promotes cancer progression by modulating m6A modifications to suppress target gene translation
Wu, G., Suo, C., Yang, Y., Shen, S., Sun, L., Li, S., Zhou, Y., Yang, D., Wang, Y., Cai, Y., et al. (2021) · EMBO Reports · doi:10.15252/embr.202051519 · Cited by 44
Integrated requirement of non‐specific and sequence‐specific DNA binding in Myc‐driven transcription
Pellanda, P., Dalsass, M., Filipuzzi, M., Loffreda, A., Verrecchia, A., Cano, V. C., Thabussot, H., Doni, M., Morelli, M. J., Soucek, L., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105464 · Cited by 44
T cells at work: How post‐transcriptional mechanisms control T cell homeostasis and activation
Jurgens, A. P., Popović, B., & Wolkers, M. C. (2021) · European Journal of Immunology · doi:10.1002/eji.202049055 · Cited by 42
Drugging the ‘undruggable’. Therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods
Radaeva, M., Ton, A., Hsing, M., Ban, F., & Cherkasov, A. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.018 · Cited by 46
Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer
Fairlie, W. D., & Lee, E. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062841 · Cited by 45
Regulatory Mechanisms of LncRNAs in Cancer Glycolysis: Facts and Perspectives
Huang, P., Zhu, S., Liang, X., Zhang, Q., Luo, X., Liu, C., & Song, L. (2021) · Cancer Management and Research · doi:10.2147/cmar.s314502 · Cited by 43
Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness
Mathsyaraja, H., Catchpole, J., Freie, B. W., Eastwood, E., Babaeva, E., Geuenich, M., Cheng, P. F., Ayers, J., Yu, M., Wu, N., et al. (2021) · eLife · doi:10.7554/elife.64212 · Cited by 40
eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis
Ruan, H., Li, X., Xu, X. M., Leibowitz, B. J., Tong, J., Chen, L., Ao, L., Xing, W., Luo, J., Yu, Y., et al. (2020) · eLife · doi:10.7554/elife.60151 · Cited by 41
Strategies to target the cancer driver MYC in tumor cells
Weber, L. I., & Hartl, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1142111 · Cited by 43
Trametinib Inhibits the Growth and Aerobic Glycolysis of Glioma Cells by Targeting the PKM2/c-Myc Axis
Gao, M., Yang, J., Gong, H., Lin, Y., & Liu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760055 · Cited by 37
A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma
Perri, P., Ponzoni, M., Corrias, M. V., Ceccherini, I., Candiani, S., & Bachetti, T. (2021) · Cancers · doi:10.3390/cancers13215528 · Cited by 40
MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma
Krenz, B., Gebhardt-Wolf, A., Ade, C. P., Gaballa, A., Roehrig, F., Vendelova, E., Baluapuri, A., Eilers, U., Gallant, P., D’Artista, L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1677 · Cited by 41
Self-citation
Role of c-Myc in lung cancer: Progress, challenges, and prospects
Wallbillich, N. J., & Lu, H. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.07.001 · Cited by 38
Ubiquitin-dependent regulation of transcription in development and disease
Mark, K. G., & Rapé, M. (2021) · EMBO Reports · doi:10.15252/embr.202051078 · Cited by 39
Mitochondrial fragmentation is crucial for c-Myc-driven hepatoblastoma-like liver tumors
Wang, D., Tian, J., Yan, Z., Yuan, Q., Wu, D., Liu, X., Yang, S., Guo, S., Wang, J., Yang, Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.032 · Cited by 34
Beyond gene expression: how MYC relieves transcription stress
Papadopoulos, D., Uhl, L., Ha, S. A., & Eilers, M. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.06.008 · Cited by 33
Self-citation
Targeting MYC: From understanding its biology to drug discovery
Ross, J., Miron, C. E., Plescia, J., LaPlante, P., McBride, K. M., Moitessier, N., & Möröy, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113137 · Cited by 35
Polydatin Inhibits Cell Viability, Migration, and Invasion Through Suppressing the c-Myc Expression in Human Cervical Cancer
Bai, L., Ma, Y., Wang, X., Feng, Q., Zhang, Z., Wang, S., Zhang, H., Lu, X., Xu, Y., Zhao, E., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.587218 · Cited by 34
Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
Guan, X., Yang, J., Wang, W., Zhao, B., Hu, S., Yu, D., Yuan, L., Shi, Y., Xu, J., Dong, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106703 · Cited by 33
FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity
Sahoo, S. S., Ramanand, S. G., Gao, Y., Abbas, A., Kumar, A., Cuevas, I., Li, H., Aguilar, M., Xing, C., Mani, R. S., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157574 · Cited by 32
Polyploidy and Myc Proto-Oncogenes Promote Stress Adaptation via Epigenetic Plasticity and Gene Regulatory Network Rewiring
Anatskaya, O. V., & Vinogradov, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179691 · Cited by 27
MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation
Wyn, J. D., Zimmerman, M. W., Weichert‐Leahey, N., Nunes, C., Cheung, B. B., Abraham, B. J., Beckers, A., Volders, P., Decaesteker, B., Carter, D. R., et al. (2021) · Cancers · doi:10.3390/cancers13194783 · Cited by 30
Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy
Zhou, Y., Gao, X., Meng, Y. G., Yang, B., He, Q., & Cao, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.748852 · Cited by 29
Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen
Schukur, L., Zimmermann, T., Niewoehner, O., Kerr, G., Gleim, S., Bauer-Probst, B., Knapp, B., Galli, G. G., Liang, X., Mendiola, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76960-z · Cited by 28
High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures
Roohollahi, K., de Jong, Y., van Mil, S. E., Fabius, A. W. M., Moll, A. C., & Dorsman, J. C. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100188 · Cited by 27
The initiation of mammalian embryonic transcription: to begin at the beginning
Perry, A. C. F., Asami, M., Lam, B., & Yeo, G. S. H. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.08.008 · Cited by 29
A program of successive gene expression in mouse one-cell embryos
Asami, M., Lam, B., Hoffmann, M., Suzuki, T., Lu, X., Yoshida, N., Ma, M. K. L., Rainbow, K., Gužvić, M., VerMilyea, M. D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112023 · Cited by 26
E-box binding transcription factors in cancer
Pan, Y., van der Watt, P. J., & Kay, S. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1223208 · Cited by 24
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression
Luo, C., Yu, T., Young, K. H., & Yu, L. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200016 · Cited by 24
The “Superoncogene” Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme
Cencioni, C., Scagnoli, F., Spallotta, F., Nasi, S., & Illi, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044217 · Cited by 28
Arenobufagin inhibits lung metastasis of colorectal cancer by targeting c-MYC/Nrf2 axis
Wang, M., Hu, S., Yang, J., Liang, Y., Han, L., Liang, F., Zhang, F., Zhao, H., Liu, Y., & Gao, N. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155391 · Cited by 23
Efficacy of pH-Sensitive Nanomedicines in Tumors with Different c-MYC Expression Depends on the Intratumoral Activation Profile
Shibasaki, H., Kinoh, H., Cabral, H., Quader, S., Mochida, Y., Liu, X., Toh, K., Miyano, K., Matsumoto, Y., Yamasoba, T., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c00364 · Cited by 24
MYC as a Target for Cancer Treatment: from Undruggable to Druggable?
Duffy, M. J., Tang, M., & Crown, J. P. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01169-x · Cited by 24
Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy
Cui, Z., Zou, F., Wang, R., Wang, L., Cheng, F., Wang, L., Pan, R., Guan, X., Zheng, N., & Wang, W. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03187-3 · Cited by 22
Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma
Ai, M., Ma, H., He, J., Xu, F., Ming, Y., Ye, Z., Zheng, Q., Luo, D., Yang, K., Li, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116978 · Cited by 23
Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses
Heitmeir, B., Deniz, M., Janni, W., Rack, B. K., Schochter, F., & Wiesmüller, L. (2022) · Cancers · doi:10.3390/cancers14040997 · Cited by 23
Lactobacillus paracasei BD5115-Derived 2-Hydroxy-3-Methylbutyric Acid Promotes Intestinal Epithelial Cells Proliferation by Upregulating the MYC Signaling Pathway
Qiao, Z., Wang, X., Wang, C., Jin, H., Qi, W., Zhang, H., Liu, Z., & You, C. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.799053 · Cited by 22
Upregulation of ribosome biogenesis via canonical E-boxes is required for Myc-driven proliferation
Zielke, N., Vähärautio, A., Liu, J., Kivioja, T., & Taipale, J. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.03.018 · Cited by 21
Th1-involved immune infiltrates improve neoadjuvant chemoradiotherapy response of esophageal squamous cell carcinoma
Yuan, J., Weng, Z., Tan, Z., Luo, K., Zhong, J., Xie, X., Qu, C., Lin, X., Yang, H., Wen, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215959 · Cited by 22
The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex
Papadopoulos, D., Ha, S. A., Fleischhauer, D., Uhl, L., Russell, T. J., Mikičić, I., Schneider, K., Brem, A., Valanju, O. R., Cossa, G., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.04.007 · Cited by 23
Self-citation
Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology
Duan, Y., Liu, Z., Wang, Q., Zhang, J., Liu, J., Zhang, Z., & Li, C. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101435 · Cited by 27
Protein phosphatase 1 regulatory subunit 15 A promotes translation initiation and induces G2M phase arrest during cuproptosis in cancers
Liu, C., Chen, L., Cong, Y., Cheng, L., Shuai, Y., Lv, F., Chen, K., Song, Y., & Xing, Y. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06489-w · Cited by 19
HECTD3 promotes gastric cancer progression by mediating the polyubiquitination of c-MYC
Zhang, G., Zhu, Q., Yan, X., Ci, M., Zhao, E., Hou, J., Wan, S., Lü, M., & Cui, H. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01001-9 · Cited by 19
Platycodin-D exerts its anti-cancer effect by promoting c-Myc protein ubiquitination and degradation in gastric cancer
Xu, Q., Pan, G., Wang, Z., Wang, L., Tang, Y., Dong, J., & Qin, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1138658 · Cited by 18
Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4
Wang, X., Wang, Q., Ran, K., Ren, J., Shi, Y., & Yu, L. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105238 · Cited by 18
Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs
Ciaccio, R., Rosa, P. D., Aloisi, S., Viggiano, M., Cimadom, L., Zadran, S. K., Perini, G., & Milazzo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312883 · Cited by 20
SUMOylation regulates tumorigenesis and progression: Molecular mechanisms and therapeutic applications
Wu, Y., Chen, Z., Hu, Y., Zengin, G., Zhang, Q., Li, M., & Sun, W. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70120 · Cited by 17
SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation
Hu, X., Liu, R., Hou, J., Peng, W., Wan, S., Xu, M., Li, Y., Zhang, G., Zhai, X., Liang, P., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02428-1 · Cited by 17
Regulation of SUMOylation on RNA metabolism in cancers
Cao, Y., Huang, C., Zhao, X., & Yu, J. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1137215 · Cited by 17
MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma
Pitolli, C., Marini, A., Guerra, M., Pieraccioli, M., Marabitti, V., Palluzzi, F., Giacò, L., Tamburrini, G., Cecconi, F., Nazio, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02790-2 · Cited by 17
The N-terminal α2 helix element is critical for the activity of the rice transcription factor MYC2
Zu, H., Jin, G., Kong, Y., Li, Z., Lou, Y., & Li, R. (2024) · Plant Molecular Biology · doi:10.1007/s11103-023-01411-y · Cited by 17

Authors: Baluapuri, A., Wolf, E., & Eilers, M.
Affiliations: University of Würzburg (DE)
Corresponding author: Eilers, Martin
ORCID: Baluapuri, Apoorva
Wolf, Elmar
Eilers, Martin
Venue: Nature Reviews Molecular Cell Biology
Publisher: Springer Science and Business Media LLC
Published: 2020-02-18
Volume: 21
Issue: 5
Pages: 255-267
ISSN: 1471-0072 (ISSN-L)
1471-0080
DOI: 10.1038/s41580-020-0215-2
PMC: PMC7611238
OpenAlex: W3007097494
Cited by: 310
References: 130
Citations by year: 2026: 29 · 2025: 48 · 2024: 63 · 2023: 60 · 2022: 50 · 2021: 51 · 2020: 9
FWCI: 4.09
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Molecular Cell Biology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: Myc oncoprotein, MYCN, transcription factors, target genes, RNA polymerase II stalling, transcription termination, transcription elongation, DNA replication, cell cycle progression, stress resilience, basal transcription, carcinogenesis, protein-protein interaction network, transcriptional regulation
MeSH terms: N-Myc Proto-Oncogene Protein, Cell Cycle, DNA Replication, Humans, Neoplasms, Transcription Factors, Transcription, Genetic, Oncogene Proteins, Proto-Oncogene Proteins c-myc, Cell Proliferation, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Target gene-independent functions of MYC oncoproteins

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks